Document is current
Any future updates will be listed below
-
Authors
Gomides, Ana Paula Monteiro https://orcid.org/0000-0003-2884-2210
de Albuquerque, Cleandro Pires
da Mota, Licia Maria Henrique
Devidé, Guilherme
Dias, Laiza Hombre
Duarte, Angela Luzia Branco Pinto
Giovelli, Raquel Altoé
Karnopp, Thais Evelyn
de Lima, Hugo Deleon
Marinho, Adriana
de Oliveira, Marianne Schrader
Omura, Felipe
Ranzolin, Aline
Resende, Gustavo
Ribeiro, Francinne Machado
Ribeiro, Sandra Lúcia Euzébio
de Carvalho Sacilotto, Nathália
dos Santos, Wander Gonzaga
Shinjo, Samuel Katsuyuki
de Sousa Studart, Samia Araujo
Teixeira, Flávia Patricia Sena
Yazbek, Michel Alexandre
Ferreira, Gilda Aparecida
Monticielo, Odirlei A.
Paiva, Eduardo
Pileggi, Gecilmara Cristina Salviato
dos Reis-Neto, Edgard Torres
de Medeiros Pinheiro, Marcelo
Marques, Claudia D. L.
,
-
Funding
Funding for this research was provided by:
Conselho Nacional de Desenvolvimento Científico e Tecnológico
- License Information
-
More Information
Article History
Received: 1 November 2021
Accepted: 10 April 2022
First Online: 3 May 2022
Declarations
:
: This study was approved by the Brazilian Committee of Ethics in Human Research on April 5, 2020, (CAAE 30186820.2.1001.8807) and registered on the Brazilian Registry of Clinical Trials (RBR-33YTQC) on June 1, 2020. All patients signed informed consent forms.
: Not applicable.
: APMG: Personal or institutional support: Pfizer, Abvie, Janssen. Advisory board: Pfizer. CPA: personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB. LMHM: Personal or institutional support from AbbVie, Janssen, Pfizer and Roche; delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB. GR: received lecture fees from Abbvie, Janssen, Novartis, Pfizer, and UCB; advisory board from Abbvie, Janssen, and Novartis; Research support from Brazilian Society of Rheumatology, FAPEMIG and UCB; Clinical research payments from Abbvie and Pfizer; sponsorship for scientific events from Abbvie, Janssen, Lilly, Novartis, Pfizer, and UCB. SLER: speeches Abbvie e Novartis. OAM: speaker’s fees from Abbvie, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, UCB and Roche. GCSP: Speeches for Jansen, Novartis. ETRN: Speeches for Janssen e Apsen. MMP: Speeches for Abbvie, Novartis, Janssen, Lilly. Advisory board: Lilly, Novartis. CDLM: Personal or institutional support from Abbvie, Janssen, Novartis, Pfizer, UCB Speeches: Abbvie, Janssen, Novartis, UCB. The other authors have no conflict of interest to declare.
